Analyzing Runway Growth Finance (NASDAQ:RWAY) and Advanced Medical Isotope (OTCMKTS:RDGL)

Advanced Medical Isotope (OTCMKTS:RDGL) and Runway Growth Finance (NASDAQ:RWAY) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Earnings and Valuation

This table compares Advanced Medical Isotope and Runway Growth Finance”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Isotope	$30,000.00	1,008.15	-$2.91 million	N/A	N/A
Runway Growth Finance	$144.63 million	2.32	$73.61 million	$1.47	6.31

Runway Growth Finance has higher revenue and earnings than Advanced Medical Isotope.

Analyst Recommendations

This is a summary of current recommendations for Advanced Medical Isotope and Runway Growth Finance, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Isotope	0	0	0	0	0.00
Runway Growth Finance	0	4	3	0	2.43

Runway Growth Finance has a consensus price target of $11.10, indicating a potential upside of 19.61%. Given Runway Growth Finance’s stronger consensus rating and higher probable upside, analysts clearly believe Runway Growth Finance is more favorable than Advanced Medical Isotope.

Profitability

This table compares Advanced Medical Isotope and Runway Growth Finance’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Advanced Medical Isotope	-6,144.90%	N/A	-113.56%
Runway Growth Finance	38.92%	11.94%	5.80%

Volatility & Risk

Advanced Medical Isotope has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500. Comparatively, Runway Growth Finance has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Insider & Institutional Ownership

64.6% of Runway Growth Finance shares are held by institutional investors. 18.5% of Advanced Medical Isotope shares are held by company insiders. Comparatively, 1.0% of Runway Growth Finance shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Runway Growth Finance beats Advanced Medical Isotope on 10 of the 12 factors compared between the two stocks.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Runway Growth Finance

Runway Growth Finance Corp. is a business development company specializing investments in senior-secured loans to late stage and growth companies. It prefers to make investments in companies engaged in the technology, life sciences, healthcare and information services, business services and select consumer services and products sectors. It prefers to investments in companies engaged in electronic equipment and instruments, systems software, hardware, storage and peripherals and specialized consumer services, application software, healthcare technology, internet software and services, data processing and outsourced services, internet retail, human resources and employment services, biotechnology, healthcare equipment and education services. It invests in senior secured loans between $10 million and $75 million.